Rollout OS for diagnostic chains launching Alzheimer's blood tests, with site QC, reference checks, and neurologist routing.

1. A blood test designed for routine diagnostic centres with two-to-five-hour results changes Alzheimer’s testing from a tertiary-only procedure into an operational rollout problem for lab networks right now.
2. If blood biomarkers can move detection earlier than PET, MRI, or cerebrospinal fluid analysis, diagnostic chains become the front door for downstream neurodiagnostic spend instead of a passive send-out channel.
3. The category has urgency because patients are still being detected too late for emerging Alzheimer’s treatments, so every month of rollout delay directly weakens the clinical value proposition.
4. Funding earmarked for assay validation, patents, and India-specific biomarker datasets implies multiple launch and localization workstreams are already underway, creating demand for infrastructure before the market standardizes.

Catalyst. eNLife’s push toward two-to-five-hour testing in routine diagnostic centres, backed by funding for validation and India-specific dataset building, makes rollout infrastructure an immediate bottleneck.

The product sits between the analyzer or LIS and the downstream neurologist as a deployment layer for novel neuro-biomarker programs. It onboards each collection centre with assay-specific readiness checks, specimen handling rules, turnaround monitoring, and site-level drift alerts before results are released. It then adds customer-approved reference logic and interpretive evidence packets so abnormal results trigger the right repeat-test, imaging, or specialist-routing workflow configured by the lab’s medical team. Early customers start with one Alzheimer’s panel, but the same stack can support every blood-based neurology assay that graduates from research into routine labs.

What's different. Assay vendors usually stop at biomarker science, while generic lab software stops at order and result transport. This company owns the unserved middle layer: distributed-site readiness, local reference modeling, and reflex workflow orchestration for fragile new neurodiagnostic assays. Over time, de-identified site-performance and downstream outcome data create a deployment moat that new assay entrants and general LIS vendors do not naturally accumulate.

Jobs to be done

flowchart LR
  Buyer[Diagnostic chain medical director] --> Pain[Distributed Alzheimer blood-test rollout risk]
  Pain --> Product[Rollout OS: site QC, reference checks, reflex routing]
  Product --> Outcome[Trusted same-day neuro biomarker program]

Executive takeaways

• Commercial reality has arrived faster than most lab software assumes: Labcorp, Quest, C2N, Roche, and Quanterix/Lucent are all commercializing Alzheimer’s blood tests, while the Alzheimer’s Association now publishes performance-based BBM guidance.[12][14][15][17][18][19][20][21][39][40]
• The operational bottleneck is distributed trust, not biomarker science: sample handling, cutoffs, and referral routing still determine whether a chain can scale beyond a tightly supervised pilot.[13][29][30][31][32][33][34][35][36]
• India is a credible wedge because dementia burden is large, diagnosis remains late, and large hub-and-spoke diagnostic networks already exist—but buyers are few, so the beachhead is commercially narrow.[1][2][3][4][5][6][7][10][11]
• The best entry point is rollout software that stays vendor-neutral across assays and escalates abnormal cases into neurologist or confirmatory pathways, rather than trying to compete head-on on assay chemistry.[10][11][13][14][15][17][20][21][39][40]

Market definition

India-first operational software for diagnostic chains launching blood-based Alzheimer’s biomarkers across distributed collection sites. The product lives between assay vendors/reference labs and the chain’s LIS, codifying sample handling, QC, interpretive cutoffs, and abnormal-case routing for symptomatic adults being evaluated for cognitive decline.[3][4][8][9][12][13][29][30][33][34]

Customer and buyer

The economic buyer is the chief medical officer, COO, or medical director of a national diagnostic chain or specialty lab group that already runs a hub-and-spoke network. Daily operators are special-assays managers, lab QA teams, and referral coordinators; neurologists and memory clinics are critical influencers because positive or indeterminate blood results still need follow-up care pathways.[1][3][4][5][6][7][13][20][21]

Buying triggers

• A decision to launch or distribute an Alzheimer’s blood test creates immediate need for standardized pre-analytics, chain-wide eligibility rules, and clean referral pathways. [10][11][12][13][14][15][17][20][21]
• Disease-modifying therapy workflows require earlier amyloid confirmation in mild cognitive impairment or mild dementia, increasing pressure to detect and triage patients before specialist slots are exhausted. [23][24][36][37][38]
• As chains move fragile assays from central experts into many collection points, sample stability, cutoff governance, and indeterminate-zone handling become board-level clinical quality risks. [29][30][33][34][35]

Willingness to pay

Budget exists when the test itself is strategically important. Nationwide launches by Labcorp, Quest, C2N, Roche, and Quanterix/Lucent show that buyers already absorb assay, routing, and compliance costs; coding and CMS gapfill activity suggest reimbursement plumbing is forming even before broad coverage stabilizes. [14][15][17][18][19][20][21][25][26][27][28][39][40]

Category dynamics

Growth signal 12% CAGR in Indian diagnostics

Validation signals

• eNLife is explicitly designing for routine diagnostic centres with two-to-five-hour turnaround and India-specific biomarker data partnerships, which makes rollout infrastructure a real bottleneck rather than a hypothetical one.
• Commercial leaders already market BBM pathways through primary or secondary care, proving the category is moving from research to operational deployment.
• Large Indian chains already run hub-and-spoke diagnostic networks extensive enough to support a central-lab-plus-distributed-collection software layer.

Regulatory & technical constraints

• Current BBM guidance and FDA-cleared labels are for symptomatic adults and adjunctive use, not open population screening or standalone diagnosis.
• Reliable deployment requires standardized handling, storage, and lot-to-lot controls; pTau may be stable, but Aβ metrics and ratios remain sensitive to pre-analytics.
• Indian commercialization still needs CDSCO-compliant IVD and regulatory documentation plus local validation plans, which favors workflow tooling over novel diagnostic claims in the first phase.

Competition is real but indirect. C2N, Quest, Labcorp/Fujirebio, Roche, and Quanterix/Lucent compete on assay availability, interpretation algorithms, or distribution reach; generic LIS workflows and manual neurologist coordination remain the default substitutes. The opening is a vendor-neutral rollout layer that helps chains run more than one assay model, manage local pre-analytics, and orchestrate follow-up without becoming locked to a single lab or analyzer vendor.[13][14][15][16][17][18][19][20][21][22][39][40]

Why incumbents do not win by default

• Assay developers. They win on biomarker chemistry and validation, but they do not own site-by-site readiness, phlebotomy drift, or customer-specific routing rules inside third-party diagnostic chains.
• National reference labs. Reference labs can distribute tests at scale, yet chains may still need their own operating layer if they want to control collection quality, multi-assay menus, or tertiary-hospital handoffs.
• Analyzer platforms. Installed analyzers shorten deployment, but instrument availability does not solve which patients to test, how to interpret indeterminate bands, or where abnormal cases go next.
• Generic LIS and middleware. Order/result plumbing is table stakes; the hard problem is versioned cutoff logic, pre-analytic enforcement, and audit-ready reflex workflows.
• Manual specialist workflows. Manual review preserves trust in small pilots, but it does not scale when blood tests widen access faster than neurologist and memory-clinic capacity grows.

Alzheimer's Assay Rollout OS should start as a vendor-neutral deployment layer for Indian diagnostic chains moving Alzheimer's blood tests from one central reference lab into 100+ collection centres. Commercialization is arriving faster than legacy lab software assumes: Labcorp, Quest, C2N, Roche, and Lucent/Quanterix already have commercial programs, and eNLife is explicitly targeting routine Indian diagnostic centres with two-to-five-hour turnaround. The first buyer is a chain medical director or CMO who has already decided to pilot an Alzheimer's blood-test menu and now owns sample-integrity, cutoff-governance, and abnormal-case handoff risk across distributed sites. The MVP should stay narrow: certify sites, enforce pre-analytic SOPs, hold questionable results, apply customer-approved dual-threshold or indeterminate workflows, and route abnormal cases into neurologist or confirmatory next steps. This is a better first product than a new assay or a generalized LIS replacement because the immediate budget sits in launch-risk reduction and clinical trust, not in biomarker discovery or wholesale workflow replacement. The near-term India Alzheimer wedge is commercially real but small, with research estimating about $11.4M TAM, $3.6M SAM, and $0.9M year-3 SOM, so venture upside depends on later expansion into additional neuro-biomarker programs or adjacent geographies. The biggest disconfirming risks are that Indian rollouts stay pilot-heavy because regulation, reimbursement, or therapy access lag, or that large labs and assay vendors bundle enough workflow support to absorb the budget. Key gaps remain the count of chains with live neurologist-linked pilots, the exact CDSCO path for imported versus local assays, and baseline sample-rejection and referral-conversion data, so the first 90 days should resolve those before scaling spend.

Problem

• Distributed collection centres can turn a clinically promising Alzheimer's blood test into a trust-destroying rollout if specimen handling, storage, and release rules are not enforced site by site.
• Generic LIS workflows, SOP binders, and spreadsheets do not manage dual thresholds, indeterminate results, or audit-ready neurologist handoff across a chain network.
• Positive or indeterminate results still need confirmatory imaging, CSF, or therapy evaluation, but specialist capacity is concentrated in tertiary centres and manual follow-up drops cases.

Solution

• Deploy a vendor-neutral rollout layer between the analyzer or LIS and the chain operations team that certifies sites, enforces pre-analytic SOPs, and holds or escalates questionable samples before results are released.
• Let each customer's medical team configure threshold bands, indeterminate handling, and reflex-workup packets so the software supports medical governance instead of making autonomous diagnostic claims.
• Track abnormal and indeterminate cases through neurologist acknowledgment or confirmatory next steps so the lab can prove its rollout closes the loop, not just generates reports.

Why we win

• Assay vendors and reference labs win on biomarker science or distribution, but they usually do not own third-party chain readiness, phlebotomy drift, or customer-specific routing logic.
• Each deployment compounds site-level QC, rerun, and India-specific interpretive data that generic LIS middleware and manual teams do not centralize.
• Closed-loop evidence on whether abnormal blood-test results reach the right next step can become a defensible workflow moat when new neuro-biomarker programs launch.

Milestones

flowchart LR
  Wedge[One-chain Alzheimer's launch wedge] --> MVP[QC and routing MVP]
  MVP --> Proof[Lower reruns and closed-loop follow-up]
  Proof --> Expansion[More sites then more neuro assays]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 4 Indian diagnostic chains must already plan neurologist-linked Alzheimer's blood-test pilots within the next 12-18 months.
• The first 3 pilots must keep preventable sample rejection and reruns below 2% and central-lab release below 24 hours at activated sites.
• Customers must accept a vendor-neutral overlay on top of their LIS and analyzer stack without requiring a full replacement project.
• At least 50% of abnormal or indeterminate cases must reach documented neurologist or confirmatory-next-step acknowledgment within 7 days when routing is enabled.
• Pilot accounts must expand to more sites or a second neuro-biomarker program within 12 months, or the wedge is too small for venture returns.

Open diligence questions

• Which Indian chains already have signed vendor or tertiary-hospital pilot agreements for Alzheimer's blood testing?
• What baseline rejection, rerun, and turnaround metrics do their special-assay launches show across 20-50 sites?
• Who controls budget and liability for rollout software when assay procurement, QA, and neurologist coordination span multiple departments?
• How much workflow support are assay vendors or large reference labs already bundling into pilot programs?
• What second assay or geography can credibly expand the business if Alzheimer's deployment remains pilot-heavy in India?

Model sanity

• Revenue engine. Base revenue comes from converting 2 Y1 pilots into 4 production chains and lifting each program toward roughly 150 active sites and about $225K steady-state annual value.
• Must go right. Pilot-to-production conversion has to stay near the BP target and the third and fourth chain wins must arrive on time or the sales-cycle sensitivity overwhelms the narrow buyer pool.
• Model breaks if. If India rollout stays pilot heavy and gross margin stalls in the mid-60s, the downside case drives cash toward roughly $0.3M before the company proves adjacent-program expansion.
• Next-round proof. The next financing case is 4 production customers plus one credible adjacent neuro-biomarker expansion decision while cash is still around $0.6M, not just more pilot logos.

Scenarios

Sensitivity

flowchart LR
  TargetChains[Target chains] --> PaidPilots[Paid pilots]
  PaidPilots --> ProductionPrograms[Production programs]
  ProductionPrograms --> SiteExpansion[More sites and workflow events]
  SiteExpansion --> Revenue[Revenue]
  Revenue --> GrossProfit[Gross profit]
  GrossProfit --> Cash[Cash and runway]

Flags: Revenue per ending FTE remains below typical SaaS benchmarks, so the seed story depends on proving adjacent-program or geography expansion rather than only the India Alzheimer wedge. · The model only works because headcount stays flat at 7 FTE from Q4Y2 through Q4Y3; hiring ahead of proof is the fastest way to compress runway. · CustomersEop includes paying pilots as well as production programs in Y1, so recurring-only production logos lag the headline count until Y2. · The base case still assumes 2 paid pilots are signed and at least one converts inside the first 12 months even though BP and research both flag unresolved buyer-timing and regulation risk. · Cash is modeled as EBITDA, so enterprise procurement timing, prepayments, or compliance-heavy launch costs could move the real cash trough earlier than the P&L suggests.

• Clinical validation lag. If Alzheimer’s blood tests take longer than expected to validate clinically or regulatorily, launch budgets could stall. Mitigation: Start as the workflow and QC layer for pilots and validation studies, then support adjacent neuro biomarkers rather than depend on one assay alone.
• Buyer timing risk. Many diagnostic chains may wait for stronger neurologist demand or reimbursement clarity before formal rollouts. Mitigation: Target chains already running special-assay launches with tertiary neurology partners and price around reduced sample failure and faster pilot expansion.
• Clinical-liability boundary. Workflow software that appears to recommend care pathways can trigger medical-governance and liability concerns. Mitigation: Keep routing logic configurable by the customer’s medical team, maintain audit trails, and position outputs as evidence-backed decision support rather than autonomous diagnosis.